Predictors of immunotherapy benefit in Merkel cell carcinoma

Merkel cell carcinoma is a rare cancer for which immune checkpoint blockade is standard-of-care for recurrent/metastatic disease. However, not all patients benefit from immunotherapy. A greater understanding of molecular mechanisms and predictive biomarkers are unmet needs. We retrospectively analyz...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Kacew, Alec J., Dharaneeswaran, Harita, Starrett, Gabriel J., Thakuria, Manisha, LeBoeuf, Nicole R., Silk, Ann W., DeCaprio, James A., Hanna, Glenn J.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2020
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7720777/
https://ncbi.nlm.nih.gov/pubmed/33315984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27823
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki